Copertina

Binding kinetics, bias, receptor internalization and effects on insulin secretion in vitro and in vivo of a novel GLP ‐ 1R / GIPR dual agonist, HISHS ‐2001

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Yusman Manchanda, Ben Jones, Gaelle Carrat, Zenouska Ramchunder, Piero Marchetti, Isabelle Leclerc, Rajamannar Thennati, Vinod Burade, Muthukumaran Natarajan, Pradeep Shahi, Alejandra Tomas, Guy A. Rutter
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Diabetes, Obesity and Metabolism
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

A metabolic comparison of GIPR agonism versus GIPR antagonism in male mice
di: Iona Davies, et al.
Pubblicazione: (2025)

Dual GIPR and GLP ‐ 1R Agonist Tirzepatide Is Associated With Fewer Asthma Exacerbations in Adults With Obesity
di: Syona Mehta, et al.
Pubblicazione: (2026)

The demise of metformin and the rise of the GLP‐1 agonists
di: Lawrence H. Price
Pubblicazione: (2026)

GLP‐1R agonist medications for addiction treatment
di: Nora D. Volkow, et al.
Pubblicazione: (2024)

GLP‐1 receptor agonists not associated with increased suicidality
Pubblicazione: (2024)

Efficacy and safety of GLP ‐1 receptor agonists and SGLT2 inhibitors as adjuncts to insulin in type 1 diabetes: Systematic review and meta‐analysis
di: Sama M. Abdel‐Rahman, et al.
Pubblicazione: (2026)

How Caron uses GLP‐1 agonists in SUD treatment
di: Alison Knopf
Pubblicazione: (2025)

Considerations on peri‐operative management of GLP ‐1 receptor agonists
di: Glenio B. Mizubuti, et al.
Pubblicazione: (2024)

Insulin requirements after switching from GLP ‐1 receptor agonist to dual GIP / GLP ‐1 receptor agonist in patients with type 2 diabetes mellitus
di: Alexa M. Lahey, et al.
Pubblicazione: (2025)

Gαs defines the fundamental coupling mechanism of insulin secretion
di: Jun Shirakawa
Pubblicazione: (2025)

Persistence of proinsulin‐only secretion in people with long‐duration diabetes and minimal residual insulin secretion
di: Sarvenaz Metghalchi, et al.
Pubblicazione: (2026)

Healthcare professionals' perceptions and management of obesity & knowledge of glucagon, GLP‐1, GIP receptor agonists, and dual agonists
di: W. Timothy Garvey, et al.
Pubblicazione: (2024)

Editorial: GLP‐1 receptor agonists in inflammatory bowel disease—Is it time?
di: Konstantinos Arvanitakis, et al.
Pubblicazione: (2024)

The hidden impact of GLP‐1 receptor agonists on endometrial receptivity and implantation
di: Alberto Sola‐Leyva, et al.
Pubblicazione: (2024)

GLP‐1 agonists and hair loss: a call for further investigation
di: Deesha D. Desai, et al.
Pubblicazione: (2024)

iGlarLixi : A titrateable fixed‐ratio combination of basal insulin + GLP‐1 receptor agonist—An effective type 2 diabetes treatment option in China
di: Miao Yu
Pubblicazione: (2025)

Residual insulin secretion in long‐standing type 1 diabetes
di: Petra Augstein, et al.
Pubblicazione: (2025)

GLP ‐1 receptor agonists and cardiovascular events in metabolically healthy or unhealthy obesity
di: Tommaso Bucci, et al.
Pubblicazione: (2025)

Considerations for evaluating the impact of GLP‐1 receptor agonist use on inpatient outcomes
di: Jessica L Schwartz, et al.
Pubblicazione: (2026)

GLP‐1 agonists and SGLT‐2 inhibitors in adults with sickle cell disease
di: Ryan Sun, et al.
Pubblicazione: (2024)

Seizure recurrence after GLP ‐1 receptor agonist initiation in adults with epilepsy
di: Majd A. AbuAlrob, et al.
Pubblicazione: (2025)

GLP‐1 agonist‐associated presentations to unscheduled care: An opportunistic pilot study
di: Oliver Thomas, et al.
Pubblicazione: (2025)

SGLT‐2 inhibitors and GLP‐1 receptor agonists for Type 2 diabetes
di: Esteban Davila, et al.
Pubblicazione: (2024)

Sildenafil amplifies calcium influx and insulin secretion in pancreatic β cells
di: Naoya Murao, et al.
Pubblicazione: (2024)

Dexmedetomidine suppresses glucose‐stimulated insulin secretion in pancreatic β‐cells
di: Munenori Kusunoki, et al.
Pubblicazione: (2024)

Dual action of imeglimin on insulin secretion and sensitivity in type 2 diabetes
di: Tsubasa Tajima, et al.
Pubblicazione: (2026)

What is the ‘real‐world’ experience with fixed‐ratio combination therapy (insulin + GLP ‐1 receptor agonist) in routine clinical practice? Take‐home messages for clinicians regarding key outcomes
di: Juan Pablo Frias
Pubblicazione: (2025)

Digital engagement enhances dual GIP / GLP ‐1 receptor agonist and GLP ‐1 receptor agonist efficacy: A retrospective cohort analysis of a digital weight loss service on outcomes and safety
di: Hans Johnson, et al.
Pubblicazione: (2025)

GLP‐1 receptor agonists for hidradenitis suppurativa: Navigating benefits, risks, and ethical considerations
di: Yaron Gu, et al.
Pubblicazione: (2024)

Psychiatric effects of GLP ‐1 receptor agonists: A systematic review of emerging evidence
di: Brianna Sa, et al.
Pubblicazione: (2025)

GLP‐1 receptor agonists and retained gastric content: Is it much ado about nothing?
di: Michael Camilleri
Pubblicazione: (2025)

Balancing procedural safety and therapeutic continuity: GLP‐1 receptor agonists and upper endoscopy
di: Lien‐Chung Wei, et al.
Pubblicazione: (2025)

Gastric point‐of‐care ultrasound in the GLP‐1 receptor agonist era: clinical impact and competency
di: Dáire N. Kelly, et al.
Pubblicazione: (2025)

Exposure to GLP‐1 receptor agonists in early pregnancy did not increase the risk of congenital malformations
di: Ilari Kuitunen
Pubblicazione: (2024)

The extent and predictors of off‐label use of GLP ‐1 receptor agonists for weight loss management
di: Zbigniew Siudak, et al.
Pubblicazione: (2025)

Metabolic inflammation and cancer risk: A potential target with GLP‐1 agonist or bariatric surgery?
di: Dillon Cheung, et al.
Pubblicazione: (2025)

GLP‐1 receptor agonists in patients with MGUS: A real‐world propensity‐matched study
di: Anastasios Tentolouris, et al.
Pubblicazione: (2025)

Less frequent dosing of GLP‐1 receptor agonists as a viable weight maintenance strategy
di: Calvin C. Wu, et al.
Pubblicazione: (2025)

GLP‐1 receptor agonists and reduced dementia risk: Real‐world evidence stacks up
di: Yun Wah Lam, et al.
Pubblicazione: (2026)

GLP ‐1 receptor agonists versus testosterone in male reproductive health: A critical perspective
di: João Oliveira Torres, et al.
Pubblicazione: (2025)